Decolonization of Enterobacteria, Such as Klebsiella Pneumoniae, from the Gut Using Strains of Klebsiella Oxytoca

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention discloses a method of preventing or treating colonization of the gut by multidrug-resistant (MDR) Enterobacteriaceae, such as Klebsiella pneumoniae, using specific probiotic strains of Klebsiella oxytoca (and related species). These beneficial bacteria, which are naturally found in some healthy humans, can outcompete harmful, antibiotic-resistant Klebsiella by utilizing certain sugars more effectively. The approach restores gut health after antibiotic use or infection, either as a therapy after colonization, or as a preventive measure before recolonization happens again.

Use CasesContent extracted from patent full text and abstract with AI.

• Use as a probiotic supplement to prevent or remove MDR Klebsiella pneumoniae and related bacteria after antibiotic treatment.
• Therapeutic administration for patients already colonized with MDR Enterobacteriaceae, especially in healthcare settings or immunocompromised individuals (e.g., after bone marrow transplant).
• Prophylactic use in hospital patients at high risk for colonization or bloodstream infection with MDR bacteria.
• Restoration of healthy gut microbiome post-antibiotic treatment, reducing recurrence of dangerous infections.
• Veterinary applications for animals at risk of colonization by resistant Enterobacteriaceae.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a non-antibiotic option to reduce or prevent colonization by dangerous, multidrug-resistant pathogens.
• Targets pathogens directly by competitive exclusion, reducing the need for broad-spectrum antibiotics that disrupt the microbiome.
• May lower the risk of serious systemic infections like bloodstream infection in vulnerable patients.
• Supports faster recovery of the normal, healthy microbiome after antibiotic use.
• Limits the spread and transmission of resistance genes, as the selected Klebsiella oxytoca strains do not carry extra antibiotic resistance traits.
• Can be used in combination with other probiotics and standard treatments for a synergistic effect.
• Applicable to multiple animal species, broadening its utility beyond human healthcare.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to probiotic bacteria of the species Klebsiella oxytoca that are used for a decolonization of multidrug resistant (MDR) Enterobacteria, such as Klebsiella pneumoniae (K. pneumoniae), from the gut of a subject. The decolonization can both be therapeutic, i.e. after colonization of the gut by the multiresistant pathogen(s), or as a preventive measure before a re-colonization of the gut, as required after antibiotic treatment.